📊 MRMD Key Takeaways
Is Marimed Inc.. (MRMD) a Good Investment?
MariMed demonstrates weak operational performance with persistent net losses (-9.1% net margin) despite modest revenue growth and positive free cash flow generation. The company's high leverage (1.52x debt/equity) combined with negative interest coverage and deteriorating profitability creates significant financial strain that outweighs the operational cash generation.
Revenue growth is minimal while operating and net margins remain negative, leading to poor ROE/ROA and an inability to cover interest from operations. Liquidity is tight (current 1.0x, quick 0.38x) and leverage is elevated (D/E 1.52x), heightening refinancing and execution risk. Positive free cash flow helped by modest capex provides some cushion, but sustainability depends on restoring operating profitability and strengthening the balance sheet.
Why Buy Marimed Inc.. Stock? MRMD Key Strengths
- Positive free cash flow of $6.5M despite net losses, indicating operational efficiency in cash conversion
- Respectable gross margin of 36.2% demonstrates pricing power and production efficiency in core operations
- Revenue growth maintained at 1.3% YoY in challenging market conditions
- Positive free cash flow with low capex needs
- Solid gross margin (36.2%) indicating viable unit economics
- Positive shareholders’ equity base
MRMD Stock Risks: Marimed Inc.. Investment Risks
- Persistent net losses of -$14.5M with negative operating margins (-1.8%) indicate fundamental profitability problems
- High leverage with debt-to-equity ratio of 1.52x and negative interest coverage (-1.7x) creates debt servicing risk
- Severely constrained liquidity with quick ratio of 0.38x and minimal cash reserves of $8.9M relative to $76M long-term debt
- Negative operating income and interest coverage (-1.7x) signal debt-service strain
- Weak liquidity (current 1.0x, quick 0.38x) limits flexibility
- Tepid revenue growth (+1.3% YoY) with persistent net losses
Key Metrics to Watch
- Path to operating profitability and trend in operating margin
- Debt service capacity and refinancing requirements given negative interest coverage
- Cash burn rate and runway given low cash balance relative to debt obligations
- Operating margin
- Interest coverage
Marimed Inc.. (MRMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 4.1% FCF margin may limit capital allocation flexibility.
MRMD Profit Margin, ROE & Profitability Analysis
MRMD vs Materials Sector: How Marimed Inc.. Compares
How Marimed Inc.. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Marimed Inc.. Stock Overvalued? MRMD Valuation Analysis 2026
Based on fundamental analysis, Marimed Inc.. shows some fundamental concerns relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Marimed Inc.. Balance Sheet: MRMD Debt, Cash & Liquidity
MRMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Marimed Inc..'s revenue has grown significantly by 32% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.03 indicates the company is currently unprofitable.
MRMD Revenue Growth, EPS Growth & YoY Performance
MRMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $40.6M | -$1.0M | $0.00 |
| Q2 2025 | $39.6M | -$1.3M | $0.00 |
| Q1 2025 | $37.9M | -$1.3M | $0.00 |
| Q3 2024 | $38.8M | -$1.0M | $0.00 |
| Q2 2024 | $36.5M | -$958.0K | $0.00 |
| Q1 2024 | $34.4M | -$645.0K | $0.00 |
| Q3 2023 | $33.9M | $2.7M | $0.01 |
| Q2 2023 | $33.0M | -$958.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Marimed Inc.. Dividends, Buybacks & Capital Allocation
MRMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Marimed Inc.. (CIK: 0001522767)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MRMD
What is the AI rating for MRMD?
Marimed Inc.. (MRMD) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MRMD's key strengths?
Claude: Positive free cash flow of $6.5M despite net losses, indicating operational efficiency in cash conversion. Respectable gross margin of 36.2% demonstrates pricing power and production efficiency in core operations. ChatGPT: Positive free cash flow with low capex needs. Solid gross margin (36.2%) indicating viable unit economics.
What are the risks of investing in MRMD?
Claude: Persistent net losses of -$14.5M with negative operating margins (-1.8%) indicate fundamental profitability problems. High leverage with debt-to-equity ratio of 1.52x and negative interest coverage (-1.7x) creates debt servicing risk. ChatGPT: Negative operating income and interest coverage (-1.7x) signal debt-service strain. Weak liquidity (current 1.0x, quick 0.38x) limits flexibility.
What is MRMD's revenue and growth?
Marimed Inc.. reported revenue of $159.8M.
Does MRMD pay dividends?
Marimed Inc.. pays dividends, with $0.0M distributed to shareholders in the trailing twelve months.
Where can I find MRMD SEC filings?
Official SEC filings for Marimed Inc.. (CIK: 0001522767) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MRMD's EPS?
Marimed Inc.. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MRMD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Marimed Inc.. has a SELL rating with 74% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MRMD stock overvalued or undervalued?
Valuation metrics for MRMD: ROE of -29.0% (sector avg: 14%), net margin of -9.1% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy MRMD stock in 2026?
Our dual AI analysis gives Marimed Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MRMD's free cash flow?
Marimed Inc..'s operating cash flow is $7.7M, with capital expenditures of $1.2M. FCF margin is 4.1%.
How does MRMD compare to other Materials stocks?
Vs Materials sector averages: Net margin -9.1% (avg: 10%), ROE -29.0% (avg: 14%), current ratio 1.00 (avg: 1.6).
Is Marimed Inc.. carrying too much debt?
MRMD has a debt-to-equity ratio of 1.52x, which is above the Materials sector average of 0.6x. However, the current ratio of 1.00 suggests adequate short-term liquidity.